GlassScriptPhysician profile
Antonios Papadopoulos
NPI 1467562116
$2,127.24
in general payments reported to CMS, 2019-2025
28 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.44 · 2020: $42.49 · 2021: $304 · 2022: $676 · 2023: $363 · 2024: $393 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $257.08 | 2019-2025 | Ozempic, Wegovy |
| Dexcom, INC. | $225.60 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $150.17 | 2022-2025 | |
| Ucb, INC. | $149.88 | 2024-2025 | Bimzelx, Cimzia |
| Amgen INC. | $124.62 | 2021-2025 | Evenity, Prolia, Repatha |
| Travere Therapeutics, INC. | $100.19 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.64 | 2021-2024 | Jardiance |
| Corcept Therapeutics | $93.59 | 2022-2023 | Korlym |
| Astrazeneca Pharmaceuticals LP | $87.34 | 2021-2024 | Farxiga |
| Lilly USA, LLC | $79.66 | 2021-2025 | Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $72.36 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $70.37 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Vifor Pharma, INC. | $66.81 | 2021-2024 | Veltassa |
| Medtronic, INC. | $64.71 | 2021-2023 | Minimed 780g |
| Recordati_rare_diseases_inc. | $62.16 | 2025 | Isturisa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $61.92 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Glaxosmithkline, LLC. | $53.26 | 2020-2024 | Trelegy Ellipta |
| Radius Health, INC. | $52.08 | 2022-2024 | Tymlos |
| Insulet Corporation | $44.68 | 2022-2025 | Omnipod |
| Amryt Pharma Holdings LTD | $42.40 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $33.29 | 2022 | |
| Daiichi Sankyo INC. | $31.80 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $28.04 | 2021-2022 | |
| Exact Sciences Corporation | $20.53 | 2024 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $18.48 | 2022 | |
| Amarin Pharma, INC. | $16.84 | 2021 | |
| Horizon Therapeutics Plc | $13.05 | 2022 | |
| Esperion Therapeutics, INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonios Papadopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.